Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 0/6 |
Past Performance | 5/6 |
Financial Health | 6/6 |
Dividends | 4/6 |
524394 Stock Overview
Vimta Labs Limited provides contract research and testing services in India and internationally.
Vimta Labs Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₹344.80 |
52 Week High | ₹453.00 |
52 Week Low | ₹216.00 |
Beta | 1.06 |
1 Month Change | -9.00% |
3 Month Change | 2.90% |
1 Year Change | 58.42% |
3 Year Change | 76.14% |
5 Year Change | 189.87% |
Change since IPO | 31,245.46% |
Recent News & Updates
Shareholder Returns
524394 | IN Life Sciences | IN Market | |
---|---|---|---|
7D | -0.9% | 1.5% | 3.4% |
1Y | 58.4% | 3.1% | 9.5% |
Return vs Industry: 524394 exceeded the Indian Life Sciences industry which returned 3.1% over the past year.
Return vs Market: 524394 exceeded the Indian Market which returned 9.5% over the past year.
Price Volatility
524394 volatility | |
---|---|
524394 Average Weekly Movement | 7.0% |
Life Sciences Industry Average Movement | 7.1% |
Market Average Movement | 7.2% |
10% most volatile stocks in IN Market | 10.0% |
10% least volatile stocks in IN Market | 4.8% |
Stable Share Price: 524394 is not significantly more volatile than the rest of Indian stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: 524394's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1984 | 1,096 | Harita Vasireddi | https://www.vimta.com |
Vimta Labs Limited provides contract research and testing services in India and internationally. The company offers laboratory, food and water testing and analysis, preclinical and clinical research, biological molecule structural and functional analysis, environmental assessment, and clinical reference laboratory services. It serves pharmaceutical, biopharmaceutical, food, consumer goods, electronic, electrical, agrochemical, healthcare, medical device, and various other industries.
Vimta Labs Fundamentals Summary
524394 fundamental statistics | |
---|---|
Market Cap | ₹7.62b |
Earnings (TTM) | ₹413.30m |
Revenue (TTM) | ₹2.78b |
18.4x
P/E Ratio2.7x
P/S RatioIs 524394 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
524394 income statement (TTM) | |
---|---|
Revenue | ₹2.78b |
Cost of Revenue | ₹791.96m |
Gross Profit | ₹1.99b |
Other Expenses | ₹1.58b |
Earnings | ₹413.30m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | 18.69 |
Gross Margin | 71.54% |
Net Profit Margin | 14.85% |
Debt/Equity Ratio | 8.3% |
How did 524394 perform over the long term?
See historical performance and comparisonDividends
0.6%
Current Dividend Yield11%
Payout RatioValuation
Is Vimta Labs undervalued compared to its fair value and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry
43.4%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 524394 (₹344.8) is trading below our estimate of fair value (₹608.78)
Significantly Below Fair Value: 524394 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 524394 is good value based on its PE Ratio (18.4x) compared to the Indian Life Sciences industry average (34.9x).
PE vs Market: 524394 is good value based on its PE Ratio (18.4x) compared to the Indian market (20.5x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 524394's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 524394 is overvalued based on its PB Ratio (3.3x) compared to the IN Life Sciences industry average (2.9x).
Future Growth
How is Vimta Labs forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score
0/6Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
21.2%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Vimta Labs has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Past Performance
How has Vimta Labs performed over the past 5 years?
Past Performance Score
5/6Past Performance Score 5/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
19.3%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 524394 has high quality earnings.
Growing Profit Margin: 524394's current net profit margins (14.9%) are higher than last year (10.1%).
Past Earnings Growth Analysis
Earnings Trend: 524394's earnings have grown by 19.3% per year over the past 5 years.
Accelerating Growth: 524394's earnings growth over the past year (93.1%) exceeds its 5-year average (19.3% per year).
Earnings vs Industry: 524394 earnings growth over the past year (93.1%) exceeded the Life Sciences industry 37.3%.
Return on Equity
High ROE: 524394's Return on Equity (17.7%) is considered low.
Financial Health
How is Vimta Labs's financial position?
Financial Health Score
6/6Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage
Financial Position Analysis
Short Term Liabilities: 524394's short term assets (₹1.2B) exceed its short term liabilities (₹477.5M).
Long Term Liabilities: 524394's short term assets (₹1.2B) exceed its long term liabilities (₹254.7M).
Debt to Equity History and Analysis
Debt Level: 524394's net debt to equity ratio (3.4%) is considered satisfactory.
Reducing Debt: 524394's debt to equity ratio has reduced from 32% to 8.3% over the past 5 years.
Debt Coverage: 524394's debt is well covered by operating cash flow (305.4%).
Interest Coverage: 524394's interest payments on its debt are well covered by EBIT (38x coverage).
Balance Sheet
Dividend
What is Vimta Labs's current dividend yield, its reliability and sustainability?
Dividend Score
3/6Dividend Score 3/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
0.58%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 524394's dividend (0.58%) is higher than the bottom 25% of dividend payers in the Indian market (0.36%).
High Dividend: 524394's dividend (0.58%) is low compared to the top 25% of dividend payers in the Indian market (1.6%).
Stability and Growth of Payments
Stable Dividend: 524394's dividend payments have been volatile in the past 10 years.
Growing Dividend: 524394's dividend payments have increased over the past 10 years.
Earnings Payout to Shareholders
Earnings Coverage: With its low payout ratio (10.7%), 524394's dividend payments are thoroughly covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its low cash payout ratio (21.7%), 524394's dividend payments are well covered by cash flows.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
5.0yrs
Average management tenure
CEO
Harita Vasireddi (47 yo)
8.83yrs
Tenure
₹6,720,000
Compensation
Ms. Harita Vasireddi, B. Pharm, MBA (USA) has been the Managing Director of Vimta Labs Ltd. since July 15, 2013 and serves as its Whole Time Director. She was a Member of Scientific Advisory Board at Vimta...
CEO Compensation Analysis
Compensation vs Market: Harita's total compensation ($USD86.36K) is above average for companies of similar size in the Indian market ($USD38.56K).
Compensation vs Earnings: Harita's compensation has been consistent with company performance over the past year.
Leadership Team
Experienced Management: 524394's management team is seasoned and experienced (5 years average tenure).
Board Members
Experienced Board: 524394's board of directors are considered experienced (3.7 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Vimta Labs Limited's employee growth, exchange listings and data sources
Key Information
- Name: Vimta Labs Limited
- Ticker: 524394
- Exchange: BSE
- Founded: 1984
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: ₹7.623b
- Shares outstanding: 22.11m
- Website: https://www.vimta.com
Number of Employees
Location
- Vimta Labs Limited
- Plot Nos. 141/2 & 142, IDA, Phase II
- Cherlapally
- Hyderabad
- 500051
- India
Listings
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2022/05/23 00:00 |
End of Day Share Price | 2022/05/23 00:00 |
Earnings | 2022/03/31 |
Annual Earnings | 2022/03/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.